Transdermal Composite Microneedle Composed of Mesoporous Iron Oxide Nanoraspberry and PVA for Androgenetic Alopecia Treatment

Polymers

Yin-Yu Chen¹  Jen-Hung Fang¹  Shang-Hsiu Hu¹  Che-Hau Liu¹  Ru-Siou Hsu¹  Wen-Hsuan Chiang²  Hui-MinDavid Wang³ 

[1] Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 300, Taiwan;Department of Chemical Engineering, National Chung Hsing University, Taichung 402, Taiwan;Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung 402, Taiwan;

关键词: 3D printing process;    mesoporous iron oxide;    microneedles;    minoxidil;   

DOI  :  10.3390/polym12061392

来源: DOAJ

【 摘 要 】

The transdermal delivery of therapeutic agents amplifying a local concentration of active molecules have received considerable attention in wide biomedical applications, especially in vaccine development and medical beauty. Unlike oral or subcutaneous injections, this approach can not only avoid the loss of efficacy of oral drugs due to the liver’s first-pass effect but also reduce the risk of infection by subcutaneous injection. In this study, a magneto-responsive transdermal composite microneedle (MNs) with a mesoporous iron oxide nanoraspberry (MIO), that can improve the drug delivery efficiency, was fabricated by using a 3D printing-molding method. With loading of Minoxidil (Mx, a medication commonly used to slow the progression of hair loss and speed the process of hair regrowth), MNs can break the barrier of the stratum corneum through the puncture ability, and control the delivery dose for treating androgenetic alopecia (AGA). By 3D printing process, the sizes and morphologies of MNs is able to be, easily, architected. The MIOs were embedded into the tip of MNs which can deliver Mx as well as generate mild heating for hair growth, which is potentially attributed by the expansion of hair follicle and drug penetration. Compared to the mice without any treatments, the hair density of mice exhibited an 800% improvement after being treated by MNs with MF at 10-days post-treatment.

【 授权许可】

Unknown